DBV Technologies S.A. (DBVT) stock
DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF
$9.99−0.28 (-2.73%)
Close on Nov 17, 2026Market cap $628.15MP/E –Yield –
DBV Technologies free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
DBV Technologies's free cash flow for the twelve months ending Sep 30, 2026 was -$191.71M. For fiscal 2025 it was -$121.71M. The highest annual figure on record is -$56.42M in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$121.71M | – |
| FY2024 | Dec 31, 2024 | -$106.81M | – |
| FY2023 | Dec 31, 2023 | -$80.33M | – |
| FY2022 | Dec 31, 2022 | -$56.42M | – |
| FY2021 | Dec 31, 2021 | -$109.15M | – |
| FY2020 | Dec 31, 2020 | -$168.40M | – |
| FY2019 | Dec 31, 2019 | -$153.91M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$53.70M | – |
| Q2 FY2026 | Jun 30, 2026 | -$53.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$49.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$35.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.60M | – |
| Q2 FY2025 | Jun 30, 2025 | -$33.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.13M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$35.81M | – |
| Q1 FY2024 | Mar 31, 2024 | -$36.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.04M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.62M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.72M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.90M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.49M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.13M | – |
| Q1 FY2021 | Mar 31, 2021 | -$36.39M | – |
| Q2 FY2020 | Jun 30, 2020 | -$40.78M | – |
| Q1 FY2020 | Mar 31, 2020 | -$50.50M | – |
See a number that looks wrong?